CannRx
Science-based Cannabis Technologies
Company Overview
Snapshot
Founded in January 2017 by William Z. Levine, CannRx is a non-active startup with 1–10 employees. The company focuses on science-based cannabis technologies and has developed key innovations such as its Vapor Capture Technology, which was announced in March 2018.
Business overview
CannRx specializes in developing proprietary science-based cannabis technologies, with a focus on sleep and pain research. The company creates products for oncology support, Parkinson's disease, women's health, and recreational sports. Its core technologies include ican.sleep, a proprietary formulation for sleep disorders, and Vapor Capture Technology (VCT), an extraction method for cannabis. CannRx also works on patented nanoparticle technology to solubilize cannabinoids and terpenes, serving the pharmaceutical and medical cannabis sectors.
Strategic signal
In May 2022, CannRx ceased operations, indicating a significant shift in its market presence and strategic direction. This cessation of activity signals to investors and innovation teams that the company is no longer actively pursuing its cannabis technology development and commercialization efforts.
Log in to access full profile ›Q&A
- What are CannRx's main competitive advantages in the Health Tech & Life Sciences market? ›
- How has the company's funding evolved over time? ›
- Which customers or partners use CannRx's technology? ›
- What is CannRx's intellectual property portfolio? ›
- Who are the key competitors in the Health Tech & Life Sciences space? ›